# SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct07700667/  
OnCo record `nct07700667` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07700667 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 120 participants planned, started 2026-08-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500, Tislelizumab, Cisplatin and 5 - FU.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07700667
- Phase: 2
- Setting: A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07700667: https://clinicaltrials.gov/study/NCT07700667

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07700667.json